The Rafah border crossing, Gaza's sole gateway to Egypt, has partially reopened for pedestrian traffic after a prolonged Israeli closure, offering a fragile hope for medical evacuations and family reunifications.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
Despite a brutal 50% share price plunge over three months, Reitar Logtech Holdings (NASDAQ:RITR) exhibits underlying financial resilience. While its Return on Equity appears weak, the company's aggressive reinvestment strategy has fueled a remarkable 26% net income growth over five years, starkly outperforming its struggling industry. This analysis delves into the disconnect between short-term market sentiment and the firm's long-term operational engine.
The all-stock deal creates a top-tier independent producer focused on the Permian Basin, with Beth McDonald at the helm aiming to unlock significant synergies and shareholder returns.
Essar Oil and Gas Exploration & Production (EOGEPL) is injecting $100 million into its flagship Raniganj East CBM block in West Bengal, aiming to scale up domestic natural gas production and explore shale potential in a bid to reduce India's import reliance.
A new financial analysis suggests shares of the documentary-focused streaming service CuriosityStream may be trading significantly below their estimated intrinsic value, presenting a potential opportunity for investors.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Eastern Bankshares (EBC) concludes a transformative year, reporting full-year 2025 results, affirming its dividend, and completing a share repurchase. The moves have propelled its stock, raising questions about its valuation amidst a shifting banking landscape.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Shares of Empire State Realty Trust (ESRT) are trading at $6.63, presenting investors with a conundrum: a narrative suggesting undervaluation clashes with a premium price-to-earnings multiple. We examine the divergence and what it means for the iconic property owner.
A deep dive into Truist Financial's valuation suggests its current share price may not fully reflect its underlying earnings power and book value, presenting a potential opportunity for investors.
Amidst a cautiously optimistic economic backdrop in Europe, we examine three publicly traded companies with market capitalizations exceeding €30 million that combine the growth potential of small-caps with notable financial resilience.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Five years after its peak, Polkadot (DOT) trades at a staggering 97% discount from its all-time high. Once a top-tier crypto, it has now fallen outside the top 30. We examine whether its steep discount represents a hidden opportunity or a sign of a failed thesis in a market now dominated by Ethereum and Solana.
The rapid adoption of OpenClaw, an open-source autonomous AI agent platform, is moving beyond social media buzz to directly execute transactions on blockchain networks, prompting both excitement about efficiency and deep concerns over market stability and accountability.
Bassett Furniture Industries (NASDAQ: BSET) has seen significant price swings in recent months, drawing investor scrutiny. With a current trading price well below its calculated intrinsic value and a bullish earnings forecast, analysts are debating whether this small-cap furniture maker presents a timely buying opportunity.
